Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹1,695 Cr revenue.
COGS 27.5%, employees 32.4%.
“revenues stood at $5.”
“Y o Y increase of 27% compared to $4.”
“Profit after tax for the quarter was INR100 crores, up 86% year on year.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 14.7%▲ | 10.5% |
| ROCE | 19.1%▲ | 13.8% |
| Net Margin | 15.0%▲ | 8.7% |
| EBITDA Margin | 29.2%▲ | 16.0% |
| Debt To Equity | 0.09x▼ | 0.21x |
| (₹ Cr) | TTM | FY2025 |
|---|---|---|
| Revenue | ₹2,170 Cr +28.0% | ₹1,695 Cr |
| Other Income | ₹43 Cr +17.5% | ₹37 Cr |
| Total Income | ₹2,213 Cr +27.8% | ₹1,731 Cr |
| COGS | ₹577 Cr +23.9% | ₹466 Cr |
| ₹1,759 Cr +17.0% | ₹1,504 Cr | |
| Profit Before Tax | ₹446 Cr +95.8% | ₹228 Cr |
| Exceptional Items | (₹8 Cr) | ₹0.00 Cr |
| ₹113 Cr +96.0% | ₹58 Cr | |
| Net Profit | ₹333 Cr +95.7% | ₹170 Cr |
| Profit (Owners) | ₹333 Cr +95.7% | ₹170 Cr |
| Other Comprehensive Income | (₹4 Cr) ↓ Decline | ₹1 Cr |
| EPS | ₹15.89 | ₹8.16 |
| Diluted Shares | ₹21 Cr | ₹21 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Sai Life Sciences Limited has informed the Exchange about Schedule of meeting with analyst / Investor on 3rd and 4th June 2026 at Mumbai
Sai Life Sciences Limited has informed the Exchange about Transcript of Earnings Call for the Audited Financial Results of the Company for the quarter and year ended 31 March 2026.
Sai Life Sciences Limited has informed the Exchange regarding Allotment of 92000 Shares under ESOP Schemes of the Company.
Monitoring Agency Report for the quarter and year ended 31 March 2026
Sai Life Sciences Limited has informed the Exchange about Investor Presentation
Sai Life Sciences Limited has informed the Exchange regarding a press release dated May 11, 2026, titled "Achievement of 100% Renewable Power at Bidar Campus of theCompany".
Earnings conference call invite for the quarter and year ended Financial Results ended on 31 March, 2026
Intimation of an Order dated 29th April 2026 issued by the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi u/s 107 (11) of the Central Goods and Services Tax Act, 2017 and the Karnataka G...
Sai Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Sai Life Sciences Limited has informed the Exchange regarding Allotment of 11,100 Equity Shares under ESOP 2008 Scheme of the Company.
Sai Life Sciences Limited has informed the Exchange about an order dated 18th March 2026 passed by the Deputy Commissioner of Income Tax (International Taxation) Hyderabad u/s 201 (1) of the Income Ta...
Sai Life Sciences Limited has informed the Exchange about Schedule of meet
Sai Life Sciences Limited has informed the Exchange regarding revised Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Allotment of equity shares under Employees Stock Option Plan...
Sai Life Sciences Limited has informed the Exchange regarding Allotment of 129007 Equity Shares under ESOP Schemes.
Sai Life Sciences Limited has informed the Exchange about Schedule of meet
No dividend history available for this company.